The Effect of Mild Weight Loss on Circulating Metabolite Profiles

Sponsor
Yonsei University (Other)
Overall Status
Completed
CT.gov ID
NCT03135132
Collaborator
(none)
100
1
2
16
6.2

Study Details

Study Description

Brief Summary

To determine whether low calorie diet (LCD)-induced weight reduction caused changes in plasma metabolites and metabolic traits from baseline.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Control group
  • Behavioral: LCD group
N/A

Detailed Description

Over a 12-week clinical intervention period, a randomized, controlled study was carried out; overweight subjects consumed a LCD (approximately 300kcal/d deficit, n=47) or a weight-maintenance diet (control, n=50) were included for analyzing plasma samples and metabolites using an ultra-performance liquid chromatography and mass spectrometry (UPLC-LTQ/Orbitrap MS).

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Metabolomics Identifies Increases in Acylcarnitine Profiles in Plasma of Overweight Subjects in Response to Mild Weight Loss
Actual Study Start Date :
Jun 1, 2015
Actual Primary Completion Date :
Oct 1, 2016
Actual Study Completion Date :
Oct 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Control group

Usual dietary intake group

Behavioral: Control group
Recommend to consume usual diet during 12-week study period

Experimental: LCD group

Low calorie diet (LCD) group (300kcal/day intake reduction)

Behavioral: LCD group
Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day

Outcome Measures

Primary Outcome Measures

  1. Visceral fat area at L4 (CT) [At baseline]

  2. Visceral fat area at L4 (CT) [At 12-week follow-up]

  3. Change in visceral fat area at L4 from baseline [At baseline and 12-week follow-up]

  4. Putatively identified plasma metabolites (Normalized peak intensities) [At baseline]

  5. Putatively identified plasma metabolites (Normalized peak intensities) [At 12-week follow-up]

  6. Changes in putatively identified plasma metabolites (Normalized peak intensities) from baseline [At baseline and 12-week follow-up]

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Able to give informed consent

  • 20-65 years old

  • Males and females

  • Overweight (25.0 kg/m²≤ Body mass index <30 kg/m²)

  • Nondiabetic (Fasting glucose <126 mg/dL)

Exclusion Criteria:
  • Unstable body weight (body weight change >1 kg within 3 months before screening)

  • Consumption of medication that affects body weight or energy expenditure

  • Pregnancy or breast-feeding

  • Hypertension, type 2 diabetes, cardiovascular disease, cerebrovascular disease, or thyroid disease

  • Liver disease, kidney disease, or gastrointestinal disease

  • Acute or chronic infections

  • Any acute or chronic disease requiring treatment

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yonsei University Seoul Korea, Republic of 03722

Sponsors and Collaborators

  • Yonsei University

Investigators

  • Principal Investigator: Jong Ho Lee, PhD, Yonsei University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yonsei University
ClinicalTrials.gov Identifier:
NCT03135132
Other Study ID Numbers:
  • Wt loss_metabolites
First Posted:
May 1, 2017
Last Update Posted:
May 1, 2017
Last Verified:
Apr 1, 2017
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yonsei University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 1, 2017